Compare · DGX vs HUM
DGX vs HUM
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $51.90B, about 2.0x DGX ($26.40B).
- Over the past year, DGX is up 24.0% and HUM is up 50.2% - HUM leads by 26.2 points.
- HUM has been more active in the news (13 items in the past 4 weeks vs 5 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Humana Inc.
- Price
- $235.03-1.68%
- $413.06-4.40%
- Market cap
- $26.40B
- $51.90B
- 1M return
- -5.07%
- +7.44%
- 1Y return
- +24.01%
- +50.19%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest DGX
- SEC Form 8-K filed by Quest Diagnostics Incorporated
- SEC Form 4 filed by Director Wentworth Timothy C
- Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
- Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- CEO and President Davis J. E. sold $2,427,200 worth of shares (10,000 units at $242.72) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 122,423 units (SEC Form 4)
- SVP & General Counsel Prevoznik Michael E exercised 22,677 shares at a strike of $112.17, sold $5,513,083 worth of shares (22,677 units at $243.11) as part of a pre-agreed trading plan and gifted 1,000 shares, decreasing direct ownership by 3% to 36,557 units (SEC Form 4)
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
Latest HUM
- Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
- SEC Form 8-K filed by Humana Inc.
- Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
- Humana upgraded by Raymond James with a new price target
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- Humana upgraded by Robert W. Baird with a new price target
- Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
- SEC Form 8-K filed by Humana Inc.
- Humana upgraded by Cantor Fitzgerald with a new price target
- Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds